Evidence map›Paper›PMID 25775247›Full record

ArticlePloS one2015

The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces.

Caileen M Brison, Steven M Mullen, Michelle E Wuerth, Kira Podolsky, Matthew Cook, Jacob A Herman, Justin D Walter, Shannon L Meeks, P Clint Spiegel

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Caileen M BrisonWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Steven M MullenWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Michelle E WuerthWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Kira PodolskyWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Matthew CookWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Jacob A HermanWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Justin D WalterWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Shannon L MeeksAflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University, Atlanta, Georgia, 30322, United States of America.
P Clint SpiegelWestern Washington University, Department of Chemistry, Bellingham, Washington, 98225-9150, United States of America.
Western Washington University · USCenter for Cancer and Blood Disorders · US

Funding

Translational Research SkillsU54HL112309 · NHLBI · EMORY UNIVERSITY · PI LOLLAR, JOHN S. · 2012 to 2016
$12.1M
Structure and Stability Studies of Factor VIII to Overcome the Immune ResponseR15HL103518 · NHLBI · WESTERN WASHINGTON UNIVERSITY · PI SPIEGEL, PAUL CLINTON · 2010 to 2010
$389k
NHLBI NIH HHS R15 HL103518NHLBI NIH HHS U54 HL112309
6 · The paper itself

Abstract

The factor VIII C2 domain is essential for binding to activated platelet surfaces as well as the cofactor activity of factor VIII in blood coagulation. Inhibitory antibodies against the C2 domain commonly develop following factor VIII replacement therapy for hemophilia A patients, or they may spontaneously arise in cases of acquired hemophilia. Porcine factor VIII is an effective therapeutic for hemophilia patients with inhibitor due to its low cross-reactivity; however, the molecular basis for this behavior is poorly understood. In this study, the X-ray crystal structure of the porcine factor VIII C2 domain was determined, and superposition of the human and porcine C2 domains demonstrates that most surface-exposed differences cluster on the face harboring the "non-classical" antibody epitopes. Furthermore, antibody-binding results illustrate that the "classical" 3E6 antibody can bind both the human and porcine C2 domains, although the inhibitory titer to human factor VIII is 41 Bethesda Units (BU)/mg IgG versus 0.8 BU/mg IgG to porcine factor VIII, while the non-classical G99 antibody does not bind to the porcine C2 domain nor inhibit porcine factor VIII activity. Further structural analysis of differences between the electrostatic surface potentials suggest that the C2 domain binds to the negatively charged phospholipid surfaces of activated platelets primarily through the 3E6 epitope region. In contrast, the G99 face, which contains residue 2227, should be distal to the membrane surface. Phospholipid binding assays indicate that both porcine and human factor VIII C2 domains bind with comparable affinities, and the human K2227A and K2227E mutants bind to phospholipid surfaces with similar affinities as well. Lastly, the G99 IgG bound to PS-immobilized factor VIII C2 domain with an apparent dissociation constant of 15.5 nM, whereas 3E6 antibody binding to PS-bound C2 domain was not observed.

Indexed as

AnimalsAntibodiesCrystallography, X-RayFactor VIIIHumansProtein Structure, QuaternaryProtein Structure, TertiarySwineAntibodiesFactor VIII

Identifiers

PMID25775247
PMCPMC4361576
OpenAlexW2018292694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.